PALIVIZUMAB

Biologic / Monoclonal Antibody

Brand names: Synagis

Intramuscular

Mechanism of Action

12.1 Mechanism of Action Palivizumab is a recombinant humanized monoclonal antibody with anti-RSV activity [see Microbiology ( 12.4 ) ].

Indications

with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season

FDA Warnings

5 WARNINGS AND PRECAUTIONS Anaphylaxis and anaphylactic shock (including fatal cases), and other severe acute hypersensitivity reactions have been reported
1 Hypersensitivity Reactions Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to Synagis

Known Side Effects

6 documented side effects by frequency

Fever

>10%

Cough

1-10%

Shortness of Breath

1-10%

Vomiting

1-10%

Upper Respiratory Infection

1-10%

Diarrhea

0.1-1%

Community Discussions

No community discussions found for PALIVIZUMAB yet.

Compare With

1 available comparisons

vs NIRSEVIMAB

Formulations

Dosage Forms

Tablet

Route

Intramuscular